Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Next generation biologics – manufacturing and supply strategies to accelerate time to market
Recent advances in technology have seen the development of many new types of biologics that have been particularly effective at targeting specific diseases. Increased complexities may lead to technical challenges resulting in longer CMC development timelines, a delay to clinical trials, and delayed commercial launches.
Points of discussion during this fireside chat: